Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corcept Therapeutics is conducting a Phase 2 study titled ‘A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS).’ The study aims to assess the safety and efficacy of dazucorilant in treating Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease.
The intervention involves administering dazucorilant, an experimental drug, in doses of 300 mg and 150 mg, compared to a placebo. The goal is to determine the drug’s effectiveness in slowing ALS progression.
This randomized, double-blind study employs a parallel intervention model with triple masking, ensuring that participants, care providers, and investigators are unaware of the treatment allocations. The primary purpose is treatment-focused.
The study began on November 15, 2022, with an anticipated primary completion date in 2025. The last update was submitted on July 24, 2025, indicating ongoing data collection and analysis.
For investors, this study could significantly impact Corcept Therapeutics’ stock, as successful results may enhance the company’s market position in the ALS treatment space. Competitors in the neurodegenerative disease sector will be closely monitoring these developments.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.